Edition:
United States

Zafgen Inc (ZFGN.OQ)

ZFGN.OQ on NASDAQ Stock Exchange Global Select Market

4.77USD
21 Apr 2017
Change (% chg)

$-0.31 (-6.10%)
Prev Close
$5.08
Open
$5.10
Day's High
$5.17
Day's Low
$4.71
Volume
91,656
Avg. Vol
69,549
52-wk High
$7.72
52-wk Low
$2.89

Latest Key Developments (Source: Significant Developments)

Zafgen reports Q4 loss per share of $0.38
Thursday, 9 Mar 2017 04:05pm EST 

Zafgen Inc : Zafgen reports fourth quarter and full year 2016 financial results . Q4 loss per share $0.38 . Q4 earnings per share view $-0.50 -- Thomson Reuters I/B/E/S .Expects Co's cash, cash equivalents and marketable securities balance will be greater than $65 million as of December 31, 2017.  Full Article

Zafgen posts Q2 shr loss $0.55
Thursday, 4 Aug 2016 04:05pm EDT 

Zafgen Inc : Q2 loss per share $0.55 . Zafgen reports second quarter 2016 financial results . Q2 earnings per share view $-0.66 -- Thomson Reuters I/B/E/S .Says expects that its cash, cash equivalents and marketable securities balance will be greater than $125 million at december 31, 2016.  Full Article

Zafgen Q1 loss per share $0.65
Tuesday, 10 May 2016 04:05pm EDT 

Zafgen Inc : Reported a net loss for q1 of $0.65 per share . Expects that its cash, cash equivalents and marketable securities balance will be greater than $100 million at December 31, 2016 . Zafgen inc says expect to have more clarity on potential path forward for beloranib in PWS over next few months . Zafgen reports first quarter 2016 financial results . Q1 loss per share $0.65 .Q1 earnings per share view $-0.74 -- Thomson Reuters I/B/E/S.  Full Article

Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Zafgen Inc and Lead Plaintiff Deadline - ACSWIR
Thursday, 17 Dec 2015 10:01am EST 

Zafgen Inc:Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed in the United States District Court for the District of Massachuesetts on behalf of those who purchased shares of Zafgen, Inc during the period between Jan.12, 2015 and Oct.16, 2015 - ACSWIR.The complaint alleges that Zafgen made false and/or misleading statements and/or failed to disclose to investors that - ACSWIR.one participant in the beloranib Phase 3 study, who had died, was receiving beloranib and not a placebo - ACSWIR.while Zafgen had reported 2 thrombotic events in prior clinical studies, there had actually been 4 such events, as well as 2 additional thrombotic events in other ongoing studies - ACSWIR.and consequently, Defendants' statements about Zafgen's business, operations and prospects were false and misleading and/or lacked a reasonable basis - ACSWIR.  Full Article

Zafgen Inc halts obesity drug trial after second patient death - Reuters
Wednesday, 2 Dec 2015 08:12pm EST 

Zafgen Inc:Zafgen Inc said the U.S. Food and Drug Administration was putting a late-stage study testing its experimental obesity drug on complete hold after a second patient died during the trial - RTRS.The company's shares fell 7.4 percent to $5.81 in extended trading after closing down 60 percent on Wednesday - RTRS.A complete clinical hold is an order that the FDA issues to a sponsor to suspend all clinical work requested under the company's investigational new drug application - RTRS.Earlier on Wednesday, the company had said a patient receiving the obesity drug, beloranib, had died from a blockage in an artery in the lungZafgen - RTRS.which is testing beloranib for a rare genetic eating disorder called Prader-Willi syndrome, expects to report results from the study in the first quarter - RTRS.The company said it was working with experts to better understand the incidence and the occurrence of such artery blockages in Prader-Willi syndrome patients - RTRS.The company said in October a patient had died in the trial, but the cause of death was unknown. Following the disclosure the FDA placed the trial under a partial clinical hold, citing previously reported blood clotting in ongoing and completed studies - RTRS.The two deaths in the 108-patient study come after clean smaller studies on the drug, where the most severe side-effect seen was bruising where the patients were given the injection - RTRS.  Full Article

FDA puts Zafgen Inc's obesity drug trials on partial hold (Oct 16) - Reuters
Sunday, 18 Oct 2015 08:00pm EDT 

Zafgen Inc:Zafgen Inc said the U.S. Food and Drug Administration has put a partial hold on the development of its obesity treatment and confirmed that the 22-year-old patient who died during a late-stage study had been taking the drug - RTRS.Zafgen expects to report results from the late-stage study in the first quarter of 2016 as the trial is nearly complete - RTRS.A second late-stage study planned on the drug will start only after the results from the first study are assessed by the FDA, the company said - RTRS.A partial clinical hold is an order the FDA issues to delay or suspend part of a company's clinical study - RTRS.Zafgen said on Wednesday the patient died during the late-stage trial testing the drug to treat Prader-Willi syndrome, a rare genetic disorder that leads to obesity - RTRS.  Full Article

Patient dies during Zafgen Inc's obesity drug trial (Oct 14) - Reuters
Sunday, 18 Oct 2015 08:00pm EDT 

Zafgen Inc:Zafgen Inc said a patient died during a late-stage trial testing the company's drug to treat Prader-Willi syndrome, a rare genetic disorder that leads to obesity - RTRS.Zafgen said it has not yet determined why the patient died and that it was working with the U.S. Food and Drug Administration to understand the cause of the death and its effect on the trial - RTRS.The company's shares, which had lost about 54 percent of its value in the past two days for no apparent reason, fell as much as 30 percent to a record low on Wednesday - RTRS.However, they reversed course over the afternoon to gain more than 30 percent over Tuesday's close - RTRS.The patient who died could have been administered a placebo rather than Zafgen's drug, beloranib, RBC analyst Simos Simeonidis said - RTRS.The trial involved 108 patients, who were randomly given either dosages of 1.8 mg, 2.4 mg or a placebo for six months - RTRS."There is still a 33 percent chance that the patient death was on the placebo arm", Simeonidis wrote in a note to clients. He reiterated his "outperform" rating on the stock - RTRS.Zafgen has said patients with the disorder have a 3% annual death rate, which would imply one or two deaths per year, suggesting it is possible the death is sporadic, Cowen and Company analysts wrote in a research note. - RTRS.The trials on beloranib started in October last year and the drug had passed all safety tests conducted by experts so far, analysts said. - RTRS.  Full Article

Zafgen Inc - Patient dies during drug trial - Reuters
Tuesday, 13 Oct 2015 08:00pm EDT 

Zafgen Inc:Drug developer's shares ZFGN.O down 30 pct at $10.97 - Reuters.Company says a patient died during late-stage trial of its experimental drug to treat rare genetic disorder that leads to obesity - Reuters.Says cause of patient's death is unknown and U.S. Food and Drug Administration has been notified - Reuters.Zafgen says it has initiated talks with FDA to expedite review and understanding of incident - Reuters.  Full Article

Zafgen Inc granted orphan drug designation in European union for beloranib
Wednesday, 30 Sep 2015 07:00am EDT 

Zafgen Inc:Granted orphan drug designation in the European union for beloranib, a first-in-class metap2 inhibitor for the treatment of craniopharyngioma.  Full Article

More From Around the Web

BRIEF-Zafgen reports Q4 loss per share of $0.38

* Zafgen reports fourth quarter and full year 2016 financial results